

Report Information

More information from: <https://www.marketresearchfuture.com/reports/anti-ageing-drugs-market-3504>

Anti-Ageing Drugs Market Research Report-Forecast till 2032

Report / Search Code: MRFR/Pharma/2408-CR

Publish Date: February, 2021

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 3250.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Global Anti-Ageing Drugs Market Overview

The anti-ageing drugs market size was valued at USD 52.11 billion in 2022 and is projected to grow from USD 55.81 Billion in 2023 to USD 90.4 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period (2023 - 2032). The rising ageing population, high levels of disposable incomes, and the influence of lifestyle industry and rising awareness are driving the market growth.

Anti-Ageing Drugs Market

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Anti-Ageing Drugs Market Trends

- **The rising ageing population to boost the market growth**

The strong and rapid increase in the world's elderly population is creating a wide range of possibilities for the development of anti-aging drugs. The growing elderly population serves as a target market for anti-aging medications, propelling the market forward. According to the World Health Organization (WHO), the number of people over 60 years old in the population is expected to double by 2050, reaching 22 percent from 12 percent in 2015.

In addition, the desire among the elderly to stay young and healthy has also grown stronger as a result of the lifestyle and fashion sectors' expanding influence. Moreover, people of all ages are becoming more interested in anti-aging medications as a consequence of rising aesthetic standards. Therefore, the use of anti-aging products has become more popular among the aging population, and this increased awareness is causing the anti-aging drugs market to experience substantial growth in the coming years.

Anti-Ageing Drugs Market Segment Insights

Anti-Ageing Drugs Drug Class Insights

The anti-ageing drugs market segmentation, based on drug class, includes serums and supplements, antioxidants and enzymes, stem cells, and drugs. The serums and supplements segment held the majority share in 2022 in the anti-ageing drugs market revenue. This is due to rise in consumer awareness about age-related skin problems such as fine lines, wrinkles, and skin dullness and increase in inclination toward spending on products that help them proclaim their skin's youthfulness. Furthermore, the majority of skin care and cosmetics products, including many other skin care and cosmetics products, are changing their design. In the upcoming years, the anti-aging serums market is anticipated to follow pace.

November 2019: Estee Lauder Inc. (US) acquired Have & Be Co. Ltd. (South Korea). The acquisition is to help further strengthen the Estée Lauder Companies' leadership position in skin care and will especially help expand the Company's consumer reach in Asia/Pacific, North America, the UK, and travel retail.

Figure 2: ANTI-AGEING DRUGS MARKET, BY DRUG CLASS, 2022 & 2030 (USD BILLION)

ANTI-AGEING DRUGS MARKET, BY DRUG CLASS, 2022 & 2030

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Anti-Ageing Drugs Application Insights

The anti-ageing drugs market segmentation, based on application, includes skin and hair, skeletal and muscles, age related disorders, and others. The skin and hair segment held the majority share in 2022 in the anti-ageing drugs market revenue. This is due to growing interest in the effectiveness of regimens and routines, increasing demand for health-promoting and self-care products. Additionally, in 2021, skincare held the top spot, making up about 41% of the worldwide market. Another 22% went to haircare products, and about 16% went to cosmetics. One of the most lucrative product categories is skincare, with sales expected to reach 188 billion dollars in 2026. About 35% of the industry as of 2021 was accounted for by the North-Asian region.

June 2021: Procter & Gamble (US) launched Nerve, a new lineup of dietary supplements developed with over 50 years of nerve care expertise, to promote healthy nerves in the US.

Anti-Ageing Drugs Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America anti-ageing drugs market accounted for largest market share. This is attributed to high disposable income, increasing awareness of aesthetic looks, and increasing awareness about ageing signs in the region. According to U.S. Census Bureau, around 83.1 million are millennial present in United Nation which represent more than one quarter of the national population. Therefore, these factors have collectively led to the expansion of anti-ageing drugs market in the region.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: ANTI-AGEING DRUGS MARKET SHARE BY REGION, 2022 & 2030 (USD BILLION)

ANTI-AGEING DRUGS MARKET SHARE BY REGION, 2022 & 2030

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe anti-ageing drugs market is expected to account for the second-largest market share due to the present of huge ageing population in the region. Further, the Germany anti-ageing drugs market is expected to hold 3rd place for the market share, and the UK anti-ageing drugs market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France anti-ageing drugs market will hold the 5th place for the market share.

The Asia-Pacific anti-ageing drugs market is expected to grow at a steady pace from 2022 to 2030. This is due to the changing lifestyle cross the region. Moreover, China anti-ageing drugs market is expected to hold the largest market share, and India anti-ageing drugs market is expected fastest-growing market in the Asia-Pacific region.

Furthermore, China continues to place among the top countries that support the growth of the skincare and cosmetics industry, including anti-aging, sun care, and skin lightening products, in terms of both production and consumption. Growing senior populations across the country will increase demand for anti-aging medications is anticipated to fuel the growth for the anti-ageing drugs market.

The Rest of the World includes the Middle East, Africa, and Latin America. This segment is projected to hold the least share in the anti-ageing drugs market. Moreover, the Middle East North Africa (MENA) and the rest of the world region is expected to see limited growth owing to abject poverty, corruption, low economic growth, unstable political conditions.

Anti-Ageing Drugs Key Market Players & Competitive Insights

The anti-ageing drugs market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Merz Pharma (Germany), Procter & Gamble (US), Nu Skin (US), and BIOTIME Inc (US) the anti-ageing drugs market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the anti-ageing drugs industry to benefit clients and expand the anti-ageing drugs market sector is to manufacture locally to reduce operating costs.

The Procter & Gamble Company (Procter & Gamble) manufactures, markets, distributes, and sells consumer packaged goods across the globe. The company operates through five business segments, namely, grooming, beauty, healthcare, fabric & home care, and baby, feminine, and family care. Its hair care category under the beauty segment includes shampoos, conditioners, and hair styling products. It sells its products through mass merchandisers, drug stores, department stores, specialty beauty stores, high-frequency stores, and pharmacies, among others. For instance, in June 2020, Elysium Health Inc. (US) introduced SIGNALTM, a unique combination of the most potent SIRT3 activators and the most direct NAD+ precursor, NMN, to support healthy mitochondrial

function and promote a healthy metabolism by replenishing essential metabolic factors lost with aging.

Also, Merz Pharma (Germany) is a aesthetic and neurotoxin company that has strong research and development capabilities. Its aesthetic products are renowned for their extraordinary quality and outstanding results. It aims to achieve and discover the needs of specialists and work in line to help patients achieve their desired results. Its skincare product portfolio offers treatments such as scars, acne, hair loss, and fungal diseases. It also operates in fields such as neurology, Over the Counter (OTC) medicines, and dietary supplements. It has a presence in more than 34 countries and offers its products in around 90 countries.

Key Companies in the Anti-Ageing Drugs Market include

- Merz Pharma (Germany)
- Procter & Gamble (US)
- Nu Skin (US)
- BIOTIME Inc (US)
- Elysium Health Inc (US)
- La Roche-Posay (UK)
- DermaFix (South Africa)
- L'Oreal (France)
- Estee Lauder Inc. (US)
- Oriflame Cosmetics (Switzerland)

Anti-Ageing Drugs Industry Developments

September 2022:La Roche-Posay (UK) launches new effaclar salicylic acid acne treatment serum with added anti-aging benefits.la roche-posay's new effaclar salicylic acid acne treatment serum is specifically formulated to target adult acne, as the clinical signs differ from adolescent acne in how they develop, where they show up, and the type of acne that occurs.

February 2020:DermaFix (South Africa) introduced Dermafix Acc Retinol +. DermaFix ACC Retinol + stimulates the fibroblasts helping to thicken the dermis for firmer and younger-looking skin. This revolutionary serum, incorporating advanced Vitamin C, resurfaces the skin whilst offering superior skin revitalization.

May 2022:La Roche-Posay (UK) launched new anti-aging face sunscreen SPF 70 daily anti-aging face sunscreen clinically tested on all skin types. The Anthelios UV Correct SPF 70 Daily Anti-Aging Face Sunscreen is formulated with Cellox-B3 Shield technology to correct and protect the skin from signs of sun damage.

January 2023:La Roche-Posay (UK) launched new anti-aging face sunscreen SPF 70 daily anti-aging face sunscreen clinically tested on all skin types. The Anthelios UV Correct SPF 70 Daily Anti-Aging Face Sunscreen is formulated with Cellox-B3 Shield technology to correct and protect the skin from signs of sun damage.

Anti-Ageing Drugs Market Segmentation

Anti-Ageing Drugs Drug Class Outlook

- Serums And Supplements

- Antioxidants And Enzymes
- Stem Cells
- Drugs

Anti-Ageing Drugs Application Outlook

- Skin And Hair
- Skeletal And Muscles
- Age Related Disorders
- Others

Anti-Ageing Drugs Regional Outlook

- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific

- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
 - Middle East
 - Africa
 - *Latin America*

Table of Content:

Contents	
1 Report Prologue	
2 Introduction	
2.1 Definition	13
2.2 Scope of Study	13
2.3 Research Objective	13
2.4 Assumptions & Limitations	14
2.4.1 Assumptions	14
2.4.2 Limitations	14
2.5 Market Structure	14
3 Research Methodology	
3.1 Research Process	15
3.2 Primary Research	16
3.3 Secondary Research	16
3.4 Market Size Estimation	16
4 Market Dynamics	
4.1 Drivers	18
4.1.1 Rising ageing population	18
4.1.2 Primal desire of humans to remain young	18
4.1.3 Influence of lifestyle industry and rising awareness	18
4.1.4 High levels of disposable incomes	18
4.2 Restraints	19
4.2.1 Scepticism and concerns of safety	19
4.2.2 Stringent regulations and definition ambiguity	19
4.3 Opportunities	19
4.3.1 Advancement in technologies and cellular understanding	19
4.3.2 Mergers, acquisitions and strategic alliances	20
4.4 Challenges	20
4.4.1 Steep competition	20
4.4.2 Ethical issues	20
4.4.3 Dubious and spurious products	20
5 Market Factor Analysis	
5.1 Porter's Five Force Analysis	21
5.1.1 Threat from a new entrant	22
5.1.2 Bargaining power of buyer	24
5.1.3 Bargaining power of supplier	24
5.1.4 Threat from substitute	24
5.1.5 Intensity of competitive rivalry	24
5.2 Supply Chain Analysis	25

5.2.1 Raw material	26
5.2.2 Supplier	26
5.2.3 Manufacturer	27
5.2.4 Distributer	27
5.2.5 Customer	28
5.2.6 Consumer	28
5.3 Technology Trends and Assessment	29
5.3.1 Caloric restriction mimetic drugs	29
5.3.2 Anti-oxidation strategy	29
5.3.3 Enzyme treatment	29
5.3.4 Nanotechnology	30
5.3.5 Genetics, cloning and strategies for engineered negligible senescence (SENS)	30
5.3.6 Hormonal therapy	31
5.4 Pipeline Analysis	31
5.4.1 Metformin in longevity study (MILES)	31
5.4.2 Vitamin D3 - Omega3 - Home Exercise (DO-HEALTH)	32
5.4.3 OpRegen	32
5.4.4 Study of Acarbose in Longevity (SAIL)	33
5.5 New Revenue Pockets Analysis	33
5.5.1 Introduction	33
5.5.2 New revenue segments	33
5.5.2.1 Stem cells and cell banking for future autologous cell therapies	33
5.5.2.2 Diseases related to ageing	34
5.5.2.3 Cryogenic preservation	34
5.5.2.4 Biomarkers	34
5.5.3 New revenue markets	34
6 Anti-Ageing Drugs Market, By Drug Class	
6.1 Introduction	35
6.2 Serums and Supplements	37
6.3 Antioxidants and Enzymes	38
6.4 Stem Cells	39
6.5 Drugs	40
7 Anti-Ageing Market, By Application	
7.1 Introduction	41
7.2 Skin and Hair	42
7.3 Skeletal and Muscles	43
7.4 Age related disorders	44
7.5 Others	45
8 Global Anti-Ageing Market, By Region	
8.1 Introduction	46
8.2 North America	48
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.2.1 US	49
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.2.2 Canada	50
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.3 Europe	52
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.3.1 Germany	53
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.3.2 France	54
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.3.3 UK	55
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.3.4 Italy	56
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.3.5 Spain	57
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.3.6 Rest of Europe	58
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.4 Asia Pacific	60
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.4.1 Japan	61
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.4.2 China	62
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.4.3 India	63
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.4.4 Australia	64
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.4.5 Republic of Korea	65
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.4.6 Rest of Asia Pacific	66
Anti-Ageing Drugs Market, By Drug Class	

Anti-Ageing Market, By Application	
8.5 Middle East and Africa	68
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.5.1 Middle east	69
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
8.5.2 Africa	70
Anti-Ageing Drugs Market, By Drug Class	
Anti-Ageing Market, By Application	
9 Company Profiles	
9.1 Nu Skin	72
9.1.1 Company Overview	72
9.1.2 Product Overview	72
9.1.3 Financial Overview	73
9.1.4 Key Developments	74
9.1.5 SWOT	76
9.2 BIOTIME, INC.	77
9.2.1 Company Overview	77
9.2.2 Product Overview	77
9.2.3 Financial Overview	77
9.2.4 Key Developments	78
9.2.5 SWOT	79
9.3 Elysium Health Inc.	80
9.3.1 Company Overview	80
9.3.2 Product Overview	80
9.3.3 Financial Overview	80
9.3.4 Key Developments	80
9.3.5 SWOT	81
9.4 La Roche-Posay	82
9.4.1 Company Overview	82
9.4.2 Product Overview	82
9.4.3 Financial Overview	82
9.4.4 Key Developments	82
9.5 L'Oréal	83
9.5.1 Company Overview	83
9.5.2 Product Overview	83
9.5.3 Financial Overview	83
9.5.4 Key Developments	85
9.5.5 SWOT	86
9.6 DermaFix	87
9.6.1 Company Overview	87
9.6.2 Product Overview	87
9.6.3 Financial Overview	87
9.6.4 Key Developments	87
9.6.5 SWOT	88
10 MRFR Conclusion	
10.1 Key Findings	89
10.1.1 From CEO's View Point	89
10.1.2 Unmet Needs	89
10.2 Key Companies to Watch	89
11 List of Tables	
TABLE 1 PIPELINE ANALYSIS	31
TABLE 2 GLOBAL ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	35
TABLE 3 GLOBAL ANTI-AGEING DRUGS MARKET FOR SERUMS AND SUPPLEMENTS BY REGION, 2020-2027 (USD MILLION)	37
TABLE 4 GLOBAL ANTI-AGEING DRUGS MARKET FOR ANTIOXIDANTS AND ENZYMES BY REGION, 2020-2027 (USD MILLION)	38
TABLE 5 GLOBAL ANTI-AGEING DRUGS MARKET FOR STEM CELLS BY REGION, 2020-2027 (USD MILLION)	39
TABLE 6 GLOBAL ANTI-AGEING DRUGS MARKET FOR DRUGS BY REGION, 2020-2027 (USD MILLION)	40
TABLE 7 GLOBAL ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	41
TABLE 8 GLOBAL ANTI-AGEING DRUGS MARKET FOR SKIN AND HAIR BY REGION, 2020-2027 (USD MILLION)	42
TABLE 9 GLOBAL ANTI-AGEING DRUGS MARKET FOR SKELETAL AND MUSCLES BY REGION, 2020-2027 (USD MILLION)	43
TABLE 10 GLOBAL ANTI-AGEING DRUGS MARKET FOR AGE RELATED DISORDERS BY REGION, 2020-2027 (USD MILLION)	44
TABLE 11 GLOBAL ANTI-AGEING DRUGS MARKET FOR OTHERS BY REGION, 2020-2027 (USD MILLION)	45
TABLE 12 GLOBAL ANTI-AGEING MARKET BY REGION, 2020-2027 (USD MILLION)	46
TABLE 13 NORTH AMERICA ANTI-AGEING MARKET BY COUNTRY, 2020-2027 (USD MILLION)	48
TABLE 14 NORTH AMERICA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	48
TABLE 15 NORTH AMERICA ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	49
TABLE 16 US ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	49
TABLE 17 US ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	50
TABLE 18 CANADA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	50
TABLE 19 CANADA ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	51
TABLE 20 EUROPE ANTI-AGEING MARKET BY COUNTRY, 2020-2027 (USD MILLION)	52
TABLE 21 EUROPE ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	52
TABLE 22 EUROPE ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	53
TABLE 23 GERMANY ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	53
TABLE 24 GERMANY ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	54
TABLE 25 FRANCE ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	54
TABLE 26 FRANCE ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	55
TABLE 27 UK ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	55
TABLE 28 U.K. ANTI-AGEING MARKET BY APPLICATIONS, 2020-2027 (USD MILLION)	56
TABLE 29 ITALY ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	56
TABLE 30 ITALY ANTI-AGEING MARKET BY APPLICATIONS, 2020-2027 (USD MILLION)	57
TABLE 31 SPAIN ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	57

TABLE 32 SPAIN ANTI-AGEING MARKET BY APPLICATIONS	58
TABLE 33 REST OF EUROPE ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	58
TABLE 34 REST OF EUROPE ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	59
TABLE 35 ASIA PACIFIC ANTI-AGEING MARKET BY COUNTRY, 2020-2027 (USD MILLION)	60
TABLE 36 ASIA PACIFIC ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	60
TABLE 37 ASIA PACIFIC ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	61
TABLE 38 JAPAN ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	61
TABLE 39 JAPAN ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	62
TABLE 40 CHINA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	62
TABLE 41 CHINA ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	63
TABLE 42 INDIA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	63
TABLE 43 INDIA ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	64
TABLE 44 AUSTRALIA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	64
TABLE 45 AUSTRALIA ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	65
TABLE 46 REPUBLIC OF KOREA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	65
TABLE 47 REPUBLIC OF KOREA ANTI-AGEING MARKET BY APPLICATION, 2020-2027 (USD MILLION)	66
TABLE 48 REST OF ASIA PACIFIC ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	66
TABLE 49 REST OF ASIA PACIFIC ANTI-AGEING MARKET BY APPLICATIONS, 2020-2027 (USD MILLION)	67
TABLE 50 MIDDLE EAST AND AFRICA ANTI-AGEING MARKET BY COUNTRY, 2020-2027 (USD MILLION)	68
TABLE 51 MIDDLE EAST AND AFRICA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	68
TABLE 52 MIDDLE EAST AND AFRICA ANTI-AGEING MARKET BY APPLICATIONS, 2020-2027 (USD MILLION)	69
TABLE 53 MIDDLE EAST ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	69
TABLE 54 MIDDLE EAST ANTI-AGEING MARKET BY APPLICATIONS, 2020-2027 (USD MILLION)	70
TABLE 55 AFRICA ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	70
TABLE 56 AFRICA ANTI-AGEING MARKET BY APPLICATIONS, 2020-2027 (USD MILLION)	71
TABLE 57 NU SKIN: KEY DEVELOPMENTS	74
TABLE 58 BIOTIME, INC.: KEY DEVELOPMENTS	78
TABLE 59 ELYSIUM HEALTH INC.:KEY DEVELOPMENTS	80
TABLE 60 L'ORÉAL :KEY DEVELOPMENTS	85

12 List of Figures

FIGURE 1 GLOBAL ANTI-AGEING DRUGS MARKET BY DRUG CLASS MARKET SHARE, 2020 (%)	11
FIGURE 2 GLOBAL ANTI-AGEING DRUGS MARKET BY APPLICATIONS MARKET SHARE, 2020 (%)	11
FIGURE 3 GLOBAL ANTI-AGEING DRUGS MARKET BY REGION MARKET SHARE, 2020 (%)	12
FIGURE 4 GLOBAL ANTI-AGING DRUGS MARKET: MARKET STRUCTURE	14
FIGURE 5 RESEARCH PROCESS OF MRFR	15
FIGURE 6 GLOBAL ANTI-AGING DRUGS MARKET: PORTER FIVE FORCES ANALYSIS	22
FIGURE 7 GLOBAL ANTI-AGEING MARKET BY DRUG CLASS, 2020-2027 (USD MILLION)	36
FIGURE 8 GLOBAL ANTI-AGEING MARKET BY APPLICATIONS, 2020-2027 (USD MILLION)	42
FIGURE 9 GLOBAL ANTI-AGEING MARKET BY REGION, 2020 (%)	47
FIGURE 10 NU SKIN: RECENT FINANCIALS	73
FIGURE 11 NU SKIN: GEOGRAPHICAL MIX, 2020 (%)	73
FIGURE 12 NU SKIN: BUSINESS MIX, 2020 (%)	74
FIGURE 13 NU SKIN: SWOT ANALYSIS	76
FIGURE 14 BIOTIME INC.: RECENT FINANCIALS	77
FIGURE 15 BIOTIME, INC.: SWOT ANALYSIS	79
FIGURE 16 ELYSIUM HEALTH INC.: SWOT ANALYSIS	81
FIGURE 17 L'ORÉAL: RECENT FINANCIALS	83
FIGURE 18 L'ORÉAL: GEOGRAPHIC MIX, 2020 (%)	84
FIGURE 19 L'ORÉAL: SEGMENT MIX, 2020 (%)	84
FIGURE 20 L'ORÉAL: SWOT ANALYSIS	86
FIGURE 21 DERMAFIX: SWOT ANALYSIS	88